-

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:

  • 25th Annual Needham Virtual Healthcare Conference
  • Definium Therapeutics Investor & Analyst Day
    • Date and Time: Wednesday, April 22, 2026 from 10:00 AM – 12:00 PM EDT (followed by lunch)
    • Location: Well& by Durst, 151 W 42nd St, New York, NY 10036
    • Registration Link (in person and virtual*): Definium Therapeutics Investor & Analyst Day
      *In-person attendance is limited to invited research analysts and institutional investors.
  • Needham Virtual Psychedelics Forum
    • Panel: Clinical Risk, Regulatory Reality and the Path to Scale
    • Date and Time: Monday, April 27, 2026 at 11:00 AM EDT
      Please contact your Needham representative for access to the panel presentation.
  • 2026 RBC Capital Markets Global Healthcare Conference

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

Industry:

Definium Therapeutics, Inc.

NASDAQ:DFTX
Release Versions
English

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

More News From Definium Therapeutics, Inc.

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026...

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the closing of its previously announced underwritten public offering of 23,676,471 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase 3,088,23...

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de...
Back to Newsroom